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The Metabolomics Standards Initiative (MSI) guidelines were ﬁrst published in 2007. These guidelines
provided reporting standards for all stages of metabolomics analysis: experimental design, biological
context, chemical analysis and data processing. Since 2012, a series of public metabolomics databases
and repositories, which accept the deposition of metabolomic datasets, have arisen. In this study, the
compliance of 399 public data sets, from four major metabolomics data repositories, to the biological
context MSI reporting standards was evaluated. None of the reporting standards were complied with in
every publicly available study, although adherence rates varied greatly, from 0 to 97%. The plant
minimum reporting standards were the most complied with and the microbial and in vitro were the
least. Our results indicate the need for reassessment and revision of the existing MSI reporting
standards.
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Introduction
Leading members of the metabolomics community organised the development of the Metabolomics
Standards Initiative (MSI), following examples from other communities1,2, in 2005. This work built on
earlier efforts by the Standard Metabolic Reporting Structure initiative3 and the Architecture for
Metabolomics consortium (ArMet)4. Under the umbrella of the MSI5,6 working groups for biological
context metadata, chemical analysis, data processing, ontology and data exchange were formed. These
working groups published a series of reports, with minimal reporting standard recommendations for each
area. The MSI reports were summarized by Goodacre7. For the following 6 years, the recommendations
guided the data collection in individual labs and specialised databases8,9. Since 2012, the ﬁrst general
purpose, global repositories for metabolomics data, the European Bioinformatics Institute’s
MetaboLights10 and United States Government National Institute of Health (NIH) Metabolomics
Workbench11 have been launched. During the early phase of this emerging network of global data
exchange, the COordination of Standards in MetabOlomicS (COSMOS) consortium12 was instrumental
in ﬁlling some of the gaps in data standards and data formats. Additionally, the MetabolomeXchange
consortium that was based upon the successful ProteomeXchange13 was founded through the COSMOS
consortium.
Four metabolomics data repositories have been developed to fulﬁl the MSI guidelines for minimum
metadata reporting: MetaboLights10, Metabolomics Workbench11, Metabolomics Repository Bordeaux
(MeRy-B)9 and Metabolic Phenotype Database (MetaPhen)14,15 (Table 1). The global repositories
MetaboLights10 and Metabolomics Workbench11 accept data across a wide variety of instrumental data
formats and species. Metabolomics Workbench additionally includes the ability to perform exploratory
statistical analysis on publicly available data sets. Compared to Metabolomics Workbench, MetaboLights
has a greater focus on curation and has stricter submission guidelines. MeRy-B is a small repository,
exclusively for plant metabolomics datasets. It focuses on proton nuclear magnetic resonance (1H-NMR)
data, but also hosts gas chromatography—mass spectrometry (GC-MS) data. These three repositories are
all data providers for the MetabolomeXchange consortium. MetaPhen is part of MetabolomeExpress, a
GC-MS metabolomics data analysis platform. The majority of the studies in MetaPhen are of plants and
are GC-MS based. MetabolomeExpress is a web-server, providing processing, statistical analysis,
visualisation and data storage. A newer metabolomics repository is Global Natural Products Social
Molecular Networking (GNPS)16, which focuses on natural products. As it has no requirements for
reporting experimental metadata and does not aim to fulﬁl MSI guidelines, data from this repository has
not been included in this research.
Due to the emergence of this global network for metabolomics data exchange and dissemination, the
scientiﬁc community now has access to hundreds of public datasets for re-analysis and reuse. Data
sharing beneﬁts the community by improving reproducibility and signalling credibility of the data;
researchers who make their data publicly available demonstrate conﬁdence in their research17. This is
now widely recognised by funders, learned societies and scientists themselves and the fundamentals of
good data sharing practises have recently been revisited under the catchy acronym FAIR, which stands
for data being Findable, Accessible, Interoperable and Reproducible18. The importance of FAIR data
sharing practices are highlighted by a recent nature survey which found that two thirds of researchers are
concerned about reproducibility19. Researchers also directly beneﬁt from sharing their data—studies that
have data publicly available in a repository receive more citations than those without publicly available
data20. Examples of reuse of publicly available data from the MetaboLights repository include research
into retention time prediction21 and evaluation of the impact of normalisation methods22 and scaling23
on metabolomics data. Increasingly, journals and public funding bodies are requiring researchers to
publish their data, which will lead to further growth in the number of publicly available studies in the
coming years.
Easy to use reporting standards aid researchers in publishing their data24. Good reporting standards
also ensure consistency of metadata between datasets, and facilitate data reuse and data merger across
studies. Conversely, poor reporting standards are a burden to data reuse and do not reﬂect current
community needs25. Here, we have inspected the currently available public data sets in four metabolomics
repositories for their compliance with existing biological context MSI reporting standards in order to
assess how timely the MSI standards still are.
Database Scope Analysis No. Studies No. Public Studies No. Species
MetaboLights All Metabolomics — 435 236 77
Metabolomics Workbench All Metabolomics ✓ 505 365 40
MetaPhen Plants—GC-MS focused ✓ 115 58 17
MeRy-B Plants—1H NMR ✓ 54 30 17
Table 1. Comparison of metabolomics data repositories as of 07/03/17. The number of species refers to
the number of different species across publicly available studies only, and does not include species in private
studies.
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Results
In order to evaluate the compliance to the MSI standards three species commonly studied in biological
sciences, which were prevalent across the repositories, and encompassed four of the ﬁve MSI guidelines,
were selected for analysis. Of the four analyzed repositories, only the general purpose MetaboLights10 and
Metabolomics Workbench11 contained studies representing all three of the studied species: Homo sapiens,
Mus musculus and Arabidopsis thaliana. Neither of the plant focused repositories MetaPhen14,15 or
MeRy-B9 contained M. musculus studies, although MetaPhen contained a single H. sapiens study. In total
399 studies were analysed.
MSI Guidelines
The MSI biological context metadata working group, consisting of four subgroups, produced metadata
guidelines for the following biological experiment areas: Mammalian/ in vivo26, Microbial and in vitro27,
Plant28 and Environmental29. The Mammalian/ in vivo report is split into two sets of reporting standards:
Mammalian Clinical Trials and Human Studies and Pre-clinical. Each report consists of the minimum
reporting standards required for each class of experiment, as agreed upon by the MSI subgroup. These
standards consist of all the descriptive information about an experiment (the metadata) that was
considered crucial to the understanding of the data, in order to enable replication of the experiment and
re- or further data analysis5. As well as the minimal reporting standards, the Mammalian Clinical Trials
and Human Studies (Clinical for brevity) and Pre-clinical reports also included recommended further
information. Additional best practice reporting standards were also included in the Microbial and in vitro
report (abbreviated to in vitro). The number of metadata mandated by each minimal and optional or best
practice reporting standard was quantiﬁed (Table 2), with some guidelines being combined to obtain a
binary list (e.g. the organ and cell type standards in the Plant guidelines were combined to a single item,
as studies usually include only one of these biosources). None of the repositories contained a sufﬁcient
number of environmental studies to enable testing of compliance to the environmental set of reporting
standards.
Meta-analysis
Meta-analysis of the data shows that there are no reporting standards that are complied with in every
publicly available study (Supplementary Tables 1–7). The overall rate of compliance across repositories
varies from 0–97%. However, there are reporting standards that are complied with by every study within
a repository (Supplementary Tables 3–4, 6). Across all of the guidelines, reporting standards relating to
biosource had the highest percentage compliance.
In MetaboLights (ML) the in vitro minimal reporting standards had signiﬁcantly lower (Kruskal-
Wallis χ2= 9.37, df= 3, Po0.05) compliance compared to the pre-clinical and plant minimal reporting
standards (Fig. 1a). The plant minimum reporting standards were adhered to at a signiﬁcantly higher rate
than the three other guidelines: in vitro, clinical and pre-clinical (Kruskal-Wallis χ2= 32.05, df= 3,
Po5.2 × 10− 7) in Metabolomics Workbench (MW) (Fig. 1b). Of all the studied minimal reporting
standards, in vitro had the lowest compliance in both repositories. Conversely, the best practice in vitro
reporting standards had signiﬁcantly higher compliance than the optional clinical and pre-clinical
guidelines in MW (Supplementary Fig. 1b) and signiﬁcantly greater compliance than clinical in ML
(Supplementary Fig. 1a).
It was also found that some of the clinical studies in the repositories did not fully report the metadata
collected in the study. Instead the reporting standards were partially complied with by the reporting of
‘implicit’ metadata. Rather than reporting, for example gender, as a factor for each individual sample, the
metadata were reported as descriptive statistics in the corresponding publication to the study. In 32.76%
of clinical studies in ML and 6.93% in MW, gender was reported as implicit metadata. Both ethnicity
(ML: 13.79%, MW: 1.98%) and disease status (ML: 5.17%, MW: 3.96%) were also found to be reported as
implicit metadata in a number of studies.
There was signiﬁcantly greater compliance to the minimal reporting standards compared to the
optional for the clinical and pre-clinical guidelines within the ML (Mann-Whitney U test, clinical:
U= 118.5, Po2.1 × 10− 5, pre-clinical: U= 94, Po7.6 × 10− 4) and MW repositories (Mann-Whitney U
test, clinical: U= 78.5, Po2.1 × 10− 5, pre-clinical: U= 384.5, Po8.5 × 10− 4). However, no signiﬁcant
Standard Minimal Best Practice
Mammalian Clinical trials and human studies 22 33
Environmental 22 38
Microbial and in vitro 15 39
Plant 20 —
Pre-clinical 30 16
Table 2. The number of minimal and best practice reporting standards for each biological
experimental type. There are no additional best practice reporting standards for plant studies.
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difference was found between the compliance with the minimal and best practice in vitro reporting
standards (Fig. 2).
Across the four repositories there were signiﬁcantly different levels of compliance to the plant
guidelines (Kruskal-Wallis χ2= 8.38, df= 3, Po0.05) (Fig. 3). Overall, differences in compliance across
the four sets of reporting standards between ML and MW were not signiﬁcant (Kruskal-Wallis χ2= 2.55,
df= 3, P= 0.11).
Discussion
Our results show that the level of compliance to the different sets of reporting standards varies greatly
across public repositories. Overall the plant minimal reporting standards had the highest rate of
compliance and the microbial and in vitro had the lowest. The greater compliance to the plant guidelines
may in part be due the preciseness of their wording. Whilst all of the MSI biological context subgroup
reports encourage the use of ontologies, the plant report details precisely which ontology should be used
for the entire description of the biosource, including species, genotype, organ and cell type28. This
speciﬁcity aids ease-of-use. As there are only two A. thaliana studies in MeRy-B and three in MW, this
biases the Kruskal-Wallis test and the signiﬁcant difference between compliance to the plant reporting
standards may result from this low sample size.
Whilst similar levels of compliance to minimal and best practice microbial and in vitro reporting
standards may be due to the very low median compliance to the minimal standards, this may also stem
from how minimal and best practice reporting standards are deﬁned by the sub-working group. Only
metabolomics speciﬁc factors are included in the minimal reporting standards, whilst all other general
aspects, as well as additional factors speciﬁc to metabolomics experiments, are included in the best
practice reporting standards. This means that Cell Type and Treatment are included as best practice and
not minimal reporting standards. In all other sub-groups’ guidelines the equivalent reporting standards
are included as minimal rather than best practice. This discrepancy between guidelines should be
revisited in subsequent revisions to the MSI standards. It also supports the use of continuous revisions, as
has been adopted by the proteomics community for MIAPE2.
Lower levels of compliance to the microbial and in vitro minimal reporting standards compared to the
other sets of standards may result from researchers not understanding precisely what they are expected to
report. There is much ambiguity, for example the stability reporting standard asks ‘What is known about
the stability of (speciﬁc) metabolites during quenching, extraction and sample preprocessing?’27.
Differences in the rates of partial adherence with guidelines by reporting ‘implicit metadata’ between
MetaboLights and Metabolomics Workbench may be accounted for by the percentage of studies included
in the analysis that had an associated publication. Only 12% of human clinical studies in Metabolomics
Workbench had an associated publication, in contrast to 96% of those in MetaboLights that did. This is
Figure 1. Compliance to the MSI minimum reporting standards. Combined box-and-whisker and dot plots
showing the percentage compliance with the MSI minimum reporting standards within the (a) MetaboLights
and (b) Metabolomics Workbench repositories. Red ‘+’ indicate outliers; each ‘dot’ represents compliance to a
single reporting standard. Letters denote signiﬁcant differences in compliance (Kruskal Wallis, Dunn post-hoc
test with Benjamini-Hochberg correction).
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also true for mouse pre-clinical studies, where 30% of Metabolomics Workbench studies had an
associated publication, whereas 93% of MetaboLights studies did.
In speciﬁc instances e.g. gender in clinical H. sapiens studies (Supplementary Table 1) and age at study
start in pre-clinical M. musculus studies (Supplementary Table 3) differences in compliance between
MetaboLights and Metabolomics Workbench may result from MetaboLights more stringent submission
guidelines.
Ultimately enforcing compliance to reporting standards is the responsibility of journals and data
hosts30. If repositories do not comply with a standard, it will not be successful31. However, adhering to an
entire set of reporting standards is time-consuming and submitters may be put off sharing their data by
ambiguous wording or difﬁculty in obtaining metadata. Repositories therefore have a trade-off between
attracting users to submit their data and enforcing reporting standards to ensure deposited data is
informative. This could partially be addressed by systematically capturing experimental meta-data via
Laboratory Information Management Systems (LIMS) during experiments as proposed by Rocca-Serra
et al.24, or by tools such as mzML2ISA32 that can generate partially ﬁlled reporting templates for
MetaboLights.
The need for data sharing and reuse is now very well established18 and has been adopted and
promoted by all major funders33–36 and learned societies. In particular untargeted metabolomics holds
the promise of correlating complex patterns—molecular phenotypes—of concentration changes and
occurrences of metabolites with aspects of the exposome of an organism. In order to fulﬁl this promise
and to enable discovery of these patterns, we will inevitably need more metadata on the exposome than
most individual researchers will initially envision when designing an experiment. Furthermore, a number
of initiatives to establish computational e-infrastructures for metabolomics have recently been funded,
such as PhenoMeNal (http://phenomenal-h2020.eu) and MetaboFlow (http://europepmc.org/grantﬁnder/
results?kw=MetaboFlow&page=1). These computational infrastructures aim to provide well-tested and
reproducible workﬂows for metabolomics, where data, often from public repositories, is handed from one
workﬂow node to the next for different steps of data processing. Such computational workﬂows critically
depend on the public availability of data, well deﬁned and open data formats and compliance with a given
set of minimum information standards.
Considering that FAIR data sharing is not an end in itself but a means to enable better science and
new scientiﬁc discoveries, our results indicate a need for a) a second round of MSI consultations where
the existing standards are critically revisited and revised and b) that maintainers and curators of existing
global repositories work with publishers, funders and most importantly their users and submitters to
ensure completeness of data and metadata adhering to the existing standards. All metadata that are
required for the reanalysis and reuse of data must be captured in the updated reporting standards, to
ensure the maximum amount of information can be extracted from the data. We hope that our results
will help us convince the global metabolomics community of these needs, so that we can be instrumental
in facilitating the necessary next steps leading to revised MSI standards.
Figure 2. Comparison of Compliance to Minimal and Best Practice Reporting Standards. Box-and-whisker
plots showing the percentage compliance to the minimal and optional/best practice reporting standards in (a)
MetaboLights and (b) Metabolomics Workbench. Minimal reporting standards are indicated with ﬁlled bars,
optional/best practice reporting standards are indicated with a dot pattern and red ‘+’ indicate outliers. Mann-
Whitney U tests were used to assess signiﬁcance.
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Methods
In this research we have examined publicly available datasets to investigate their compliance with the MSI
standards. Three species with the greatest number of publicly available studies across the four repositories
were selected: Homo sapiens, Mus musculus and Arabidopsis thaliana (Supplementary Fig. 2). Four out of
the ﬁve biological experimental areas of the MSI standards are covered by studies of these species. There
are also H. sapiens and M. musculus studies that do not ﬁt within the scope of any of the existing MSI
standards, such as those of intra-laboratory differences or the development of new experimental
techniques.
Every study from the four repositories including the selected species was ﬁrst categorized by applicable
biological context standards. Some studies contain multiple assays, which can include multiple species or
both cell lines and clinical research. Multiple sets of MSI reporting standards can therefore be applicable
to a single study. For ﬁles detailing how H. sapiens andM. musculus studies were classiﬁed please see Data
Citation 1.
Following classiﬁcation, every study was examined for its compliance with the reporting of each
metadata included in the MSI guideline. For metadata to be considered reported, the metadata must be
either directly included in the repository with the data or in a publication assessable by direct link from
the study page. Raw data rating each metadata as either reported in accordance with the MSI guideline, or
not reported in accordance to the guideline are available in Data Citation 1.
Some metadata were also recorded as ‘implicit’, where the metadata were not reported on a per sample
basis, instead being reported as descriptive statistics for the entire study. Once adherence to each
metadata reporting standard had been assessed for each individual study, the percentage of studies the
metadata was reported in was calculated. The distribution of reporting of minimal/ best practice was
found for each set of standards for each repository.
Homo sapiens
Two of the MSI biological metadata reporting standards are applicable to H. sapiens: Mammalian Clinical
Trials and Human Studies and Microbial and in vitro. Human clinical trials are classiﬁed as Mammalian
Clinical Trials and Human Studies and H. sapiens cell line studies are categorized as Microbial and in
vitro studies. There are also H. sapiens studies that are neither of these experiment types and are classiﬁed
as Other.
There are 83 public H. sapiens studies in MetaboLights as of 17/03/07, 147 with the species ‘human’ in
Metabolomics Workbench and 1 H. sapiens study in MetaPhen. As there was only a single H. sapiens
study in MetaPhen, it was excluded from this research. Following classiﬁcation there were 58 Clinical, 18
in vitro and 7 Other H. sapiens studies in MetaboLights. Human Metabolomics Workbench studies
consisted of 99 Clinical, 45 in vitro and 3 Other.
Figure 3. Compliance to Plant MSI Reporting Standards. Combined box-and-whisker and dot plots showing
the percentage compliance of A. thaliana studies to the plant MSI minimum reporting standards within the
MeRy-B, MetaboLights, Metabolomics Workbench and MetaPhen repositories. Red ‘+’ indicate outliers; each
‘dot’ represents compliance to a single reporting standard. Letters denote signiﬁcant differences in compliance
(Kruskal Wallis, Dunn post-hoc test with Benjamini-Hochberg correction).
www.nature.com/sdata/
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Mus musculus
The appropriate reporting standards for use with M. musculus studies can be either Clinical, Microbial
and in vitro or Pre-clinical. However, there are also M. musculus studies that are not covered by the
existing reporting standards. In this analysis these studies are classiﬁed as Other. Across the repositories,
at the time of analysis, there were no examples of M. musculus clinical studies.
As of 17/03/07, there are 33 M. musculus studies in MetaboLights and 120 in Metabolomics
Workbench. Only studies categorized as pre-clinical were included in this work, as compliance with the
Microbial and in vitro guidelines was assessed using H. sapiens cell line studies. There are 29 M. musculus
pre-clinical studies in MetaboLights and 91 in Metabolomics Workbench.
Arabidopsis thaliana
The Plant reporting standards are broad and are applicable to all A. thaliana studies that were publicly
available in the four repositories as of 17/03/07. There were 2 A. thaliana studies from MeRy-B, 20 from
MetaboLights, 3 from Metabolomics Workbench and 37 from MetaPhen.
Statistical analysis
For analysing differences within repositories (ML and MW) Kruskal Wallis tests, followed by Dunn post-
hoc tests with Benjamini-Hochberg correction were used. A Kruskal Wallis test was also used for
comparing differences between repositories, both between ML and MW and between all four repositories
for the plant guidelines. Mann-Whitney U tests were used to analyse differences between minimal and
best practice reporting standards.
Code availability
All of the analysis was performed using R version 3.3.2. The code used for analysis is available at
https://github.com/RASpicer/Compliance_MSI_Guidelines.
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